drugset / Trial / NCT02833480

A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota

NCT02833480

RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the effects of budesonide (using Symbicort which is budesonide and formoterol) and fluticasone (using Advair which is fluticasone and salmeterol) on the airway microorganisms of patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). This is a randomized, parallel group, two-centered clinical trial study to evaluate the effects of a 12 week treatment with Symbicort 400 mcg BID and Advair 250 mcg BID (via Diskus) on airway microbiota in patients with moderate-to-severe COPD. The control arm of this study will be Oxeze 12 ug BID.

Timeline

Start
2015-02
Primary completion
2021-01
Completion
2021-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 400 ug Inhaled
Subject Fluticasone Other / unclassified 250 ug Inhaled
Comparator Formoterol Other / unclassified 12 ug Inhaled
Subject Salmeterol Other / unclassified 50 ug Inhaled